Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention

Oral Oncology

Volumn 50, Issue 10, 2014, Pages 918-923

  Mak, Milena P ^a   William, William N ^b  

^a Instituto do Câncer do Estado de São Paulo   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cetuximab; Chemoprevention; Epidermal growth factor receptor; Erlotinib; Leukoplakia; Oral premalignant lesions

Indexed keywords

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; RETINOID; VANDETANIB; ZALUTUMUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG TARGETING; GENE DOSAGE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECANCER; PROTEIN EXPRESSION; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL (TOPIC); GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM;

ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84907875359     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.12.024     Document Type: Article

References (51)

1. N. Normanno, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, and A. De Luca The ErbB receptors and their ligands in cancer: an overview Curr Drug Targets 6 3 2005 243 257
2. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578
3. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 11 2008 1116 1127
4. J.B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-Rubio, and F. Rolland Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 16 2007 2171 2177
5. J.B. Vermorken, J. Stohlmacher, I. Davidenko, L. Licitra, E. Winquist, and K. Skladowski Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (pmab) Ann Oncol 21 8 2010 abstr. LBA26
6. J.P. Machiels, S. Subramanian, A. Ruzsa, G. Repassy, I. Lifirenko, and A. Flygare Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial Lancet Oncol 12 4 2011 333 343
7. E.E. Cohen, M.A. Kane, M.A. List, B.E. Brockstein, B. Mehrotra, and D. Huo Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Clin Cancer Res 11 23 2005 8418 8424
8. E.E. Cohen, F. Rosen, W.M. Stadler, W. Recant, K. Stenson, and D. Huo Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 10 2003 1980 1987
9. J.S. Stewart, E.E. Cohen, L. Licitra, C.M. Van Herpen, C. Khorprasert, and D. Soulieres Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected] J Clin Oncol 27 11 2009 1864 1871
10. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 1 2004 77 85
11. T.Y. Seiwert, P.M. Clement, D. Cupissol, J.D. Campo, Hd Mont-Serrat, and H.C. Thurm BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study J Clin Oncol 28 15S 2010 abstr. 5501
12. W.N. William Jr., J.V. Heymach, E.S. Kim, and S.M. Lippman Molecular targets for cancer chemoprevention Nat Rev Drug Discovery 8 3 2009 213 225
13. K.K. Ang, B.A. Berkey, X. Tu, H.Z. Zhang, R. Katz, and E.H. Hammond Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 24 2002 7350 7356
14. M.C. Etienne, X. Pivot, J.L. Formento, R.J. Bensadoun, P. Formento, and O. Dassonville A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil Br J Cancer 79 11-12 1999 1864 1869
15. R. Hitt, E. Ciruelos, M.L. Amador, A. Benito, J.J. Sanchez, and C. Ballestin Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy Eur J Cancer 41 3 2005 453 460
16. J. Rubin Grandis, M.F. Melhem, W.E. Gooding, R. Day, V.A. Holst, and M.M. Wagener Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 11 1998 824 832
17. W.J. Issing, C. Liebich, T.P. Wustrow, and A. Ullrich Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer Anticancer Res 16 1 1996 283 288
18. J.R. Grandis, and D.J. Tweardy Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer Cancer Res 53 15 1993 3579 3584
19. J. Rubin Grandis, M.F. Melhem, E.L. Barnes, and D.J. Tweardy Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck Cancer 78 6 1996 1284 1292
20. D.M. Shin, J.Y. Ro, W.K. Hong, and W.N. Hittelman Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis Cancer Res 54 12 1994 3153 3159
21. M.G. van Oijen, G. Rijksen, F.W. ten Broek, and P.J. Slootweg Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse Oral Dis 4 1 1998 4 8
22. J. Rubin Grandis, D.J. Tweardy, and M.F. Melhem Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma Clin Cancer Res 4 1 1998 13 20
23. J. Rautava, K.J. Jee, P.J. Miettinen, B. Nagy, S. Myllykangas, and E.W. Odell ERBB receptors in developing, dysplastic and malignant oral epithelia Oral Oncol 44 3 2008 227 235
24. S.W. Beenken, M.T. Sellers, P. Huang, G. Peters, H. Krontiras, and P. Dixon Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid Head Neck 21 6 1999 566 573
25. M. Taoudi Benchekroun, P. Saintigny, S.M. Thomas, A.K. El-Naggar, V. Papadimitrakopoulou, and H. Ren Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer Cancer Prev Res (Phila) 3 7 2010 800 809
26. C.H. Chung, K. Ely, L. McGavran, M. Varella-Garcia, J. Parker, and N. Parker Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas J Clin Oncol 24 25 2006 4170 4176
27. S. Temam, H. Kawaguchi, A.K. El-Naggar, J. Jelinek, H. Tang, and D.D. Liu Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer J Clin Oncol 25 16 2007 2164 2170
28. N. Voravud, D.M. Shin, J.Y. Ro, J.S. Lee, W.K. Hong, and W.N. Hittelman Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis Cancer Res 53 12 1993 2874 2883
29. I.F. Tsui, C.F. Poh, C. Garnis, M.P. Rosin, L. Zhang, and W.L. Lam Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias Int J Cancer 125 9 2009 2219 2228
30. H. Nagatsuka, Y. Ishiwari, H. Tsujigiwa, K. Nakano, and N. Nagai Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions Oral Oncol 37 7 2001 599 604
31. C.F. Poh, Y. Zhu, E. Chen, K.W. Berean, L. Wu, and L. Zhang Unique FISH patterns associated with cancer progression of oral dysplasia J Dent Res 91 1 2012 52 57
32. M.G. van Oijen, M.M. Gilsing, G. Rijksen, G.J. Hordijk, and P.J. Slootweg Increased number of proliferating cells in oral epithelium from smokers and ex-smokers Oral Oncol 34 4 1998 297 303
33. D. Moraitis, B. Du, M.S. De Lorenzo, J.O. Boyle, B.B. Weksler, and E.G. Cohen Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands Cancer Res 65 2 2005 664 670
34. P.G. Sacks Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck Cancer Metastasis Rev 15 1 1996 27 51
35. B. Du, N.K. Altorki, L. Kopelovich, K. Subbaramaiah, and A.J. Dannenberg Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism Cancer Res 65 13 2005 5982 5988
36. B. Du, H. Leung, K.M. Khan, C.G. Miller, K. Subbaramaiah, and D.J. Falcone Tobacco smoke induces urokinase-type plasminogen activator and cell invasiveness: evidence for an epidermal growth factor receptor dependent mechanism Cancer Res 67 18 2007 8966 8972
37. Z.H. Gumus, B. Du, A. Kacker, J.O. Boyle, J.M. Bocker, and P. Mukherjee Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia Cancer Prev Res (Phila) 1 2 2008 100 111
38. D.M. Shin, I.B. Gimenez, J.S. Lee, K. Nishioka, M.J. Wargovich, and S. Thacher Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model Cancer Res 50 8 1990 2505 2510
39. J.J. Sheu, C.H. Hua, L. Wan, Y.J. Lin, M.T. Lai, and H.C. Tseng Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma Cancer Res 69 6 2009 2568 2576
40. R.J. Leeman-Neill, R.R. Seethala, S.V. Singh, M.L. Freilino, J.S. Bednash, and S.M. Thomas Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma Cancer Prev Res (Phila) 4 2 2011 230 237
41. J.A. Califano, R.L. Ferris, J.B. Epstein, M.B. Gillespie, L.E. Feldman, and M.K. Gibson A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract J Clin Oncol 30 suppl. 2012 [abstr. 5528]
42. L. Mao, A.K. El-Naggar, V. Papadimitrakopoulou, D.M. Shin, H.C. Shin, and Y. Fan Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy J Natl Cancer Inst 90 20 1998 1545 1551
43. V.A. Papadimitrakopoulou, J.J. Lee, W.N. William Jr., J.W. Martin, M. Thomas, and E.S. Kim Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy J Clin Oncol 27 4 2009 599 604
44. L. Mao, J.S. Lee, Y.H. Fan, J.Y. Ro, J.G. Batsakis, and S. Lippman Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment Nat Med 2 6 1996 682 685
45. M.P. Rosin, X. Cheng, C. Poh, W.L. Lam, Y. Huang, and J. Lovas Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia Clin Cancer Res 6 2 2000 357 362
46. L. Zhang, C.F. Poh, M. Williams, D.M. Laronde, K. Berean, and P.J. Gardner Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer Cancer Prev Res (Phila) 5 9 2012 1081 1089
47. M.P. Rosin, W.L. Lam, C. Poh, N.D. Le, R.J. Li, and T. Zeng 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites Cancer Res 62 22 2002 6447 6450
48. G.J. Kelloff, S.M. Lippman, A.J. Dannenberg, C.C. Sigman, H.L. Pearce, and B.J. Reid Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward Clin Cancer Res 12 12 2006 3661 3697
49. J.L. Abbruzzese, and S.M. Lippman The convergence of cancer prevention and therapy in early-phase clinical drug development Cancer Cell 6 4 2004 321 326
50. D.M. Shin, H. Zhang, N.F. Saba, A.Y. Chen, S. Nannapaneni, and A.R. Amin Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies Clin Cancer Res 19 5 2013 1244 1256
51. G. Zhou, R. Hasina, K. Wroblewski, T.P. Mankame, C.L. Doci, and M.W. Lingen Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis Cancer Prev Res (Phila) 3 11 2010 1493 1502